sorafenib has been researched along with Neoplasms in 323 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 95 (29.41) | 29.6817 |
| 2010's | 179 (55.42) | 24.3611 |
| 2020's | 49 (15.17) | 2.80 |
| Authors | Studies |
|---|---|
| Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X | 1 |
| Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE | 1 |
| Dubey, PK; Pal, M; Piedrafita, FJ; Rajitha, C; Sunku, V; Veeramaneni, VR | 1 |
| El-Gamal, MI; Lee, YS; Oh, CH; Park, JH | 1 |
| Chen, L; Huang, Z; Ling, Y; Wang, X; Wang, Z; Zhang, W; Zhang, Y; Zhu, H | 1 |
| Ding, K; Li, Y; Lu, X; Ren, X | 1 |
| Dong, H; Li, J; Ouyang, L; Song, S; Xu, C; Zhang, H | 1 |
| Gong, FH; Li, CG; Sun, LP; Wang, YJ; Xu, YG; Zhang, C; Zhang, HQ | 1 |
| Ghosh, U; Kharkar, PS; Khedkar, VM; Kulkarni, MR; Kulkarni-Almeida, A; Lad, NP; Mane, MS; Pandit, SS; Sharma, R; Srivastava, A | 1 |
| Kumarasiri, M; Philip, S; Teo, T; Wang, S; Yu, M | 1 |
| Chen, Y; Guo, H; Jin, J; Jin, Q; Li, B; Li, T; Lin, G; Ling, J; Lu, S; Lu, T; Wang, Y; Wang, Z; Yang, T; Yao, C; Yuan, H; Zhang, L; Zhi, Y | 1 |
| Agianian, B; Gavathiotis, E | 1 |
| Mostafa, AS; Selim, KB | 1 |
| Abdel-Maksoud, MS; Ammar, UM; Oh, CH | 1 |
| Cai, T; Chen, T; Du, K; Gao, X; Luo, X; Shen, R; Sun, H; Wu, C; Wu, Y; Xi, M; Yu, L | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Carda, M; Conesa-Milián, L; Falomir, E; Marco, JA; Murga, J | 1 |
| Xu, Z; Zhang, L | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Dhiman, N; Jaitak, V; Kaur, K | 1 |
| Cho, H; Choi, HG; Jeon, E; Kim, ND; Kim, S; Kim, Y; Kwon, NH; Lee, J; Moon, Y; Ryu, S; Shin, I; Sim, T; Song, C; Yoon, H | 1 |
| Acharya, B; Frett, B; Garcia, NG; Lakkaniga, NR; Ryan, KR; Saha, D; Smith, EL | 1 |
| Kurjata, J; Piorecka, K; Stanczyk, WA | 1 |
| Chen, Y; Gui, J; Huang, Y; Li, B; Liu, P; Ping, Y; Shao, B; Xu, X | 1 |
| Huang, Y; Lai, H; Qian, Z; Zhao, Y; Zhong, L | 1 |
| Di, Y; Dong, J; Liang, H; Sun, M; Yang, R; Yang, Y; Zhou, Z | 1 |
| Attia, AA; El-Magd, MA; El-Naggar, SA; Eldiasty, JG; Elmetwalli, A; Mosallam, SAE; Nasser, HM; Salama, AF | 1 |
| Abou-Alfa, GK; Cremolini, C; Crona, DJ; Etheridge, AS; Geyer, S; Hammond, K; Innocenti, F; Jacobson, SB; Marmorino, F; Peña, CE; Quintanilha, JCF; Racioppi, A; Rossini, D; Sanoff, HK | 1 |
| Akhtar, K; Arjmand, F; Khan, MA; Siddique, HR; Singh, D | 1 |
| Franco, PIG; Li, RK; Pandy, JGP | 1 |
| Huang, X; Law, BYK; Li, H; Li, W; Liu, Y; Luo, Z; Yu, Y; Zheng, Y | 1 |
| Assaraf, YG; Chen, M; Chen, ZS; Deng, L; Huang, M; Lin, Y; Wang, C; Ye, W; Zhang, D | 1 |
| Huang, P; Jiang, S; Lin, J; Zhang, Y | 1 |
| Chen, C; Chen, Y; He, L; Liu, H; Liu, X; Ouyang, Y; Sun, Y; Tan, Y; Xu, T; Zhao, S | 1 |
| Balasubramanian, V; Fernandes, M; Hirvonen, J; Hirvonen, SP; Känkänen, V; Liu, Z; Pinto, JF; Ruokolainen, J; Santos, HA; Seitsonen, J | 1 |
| Dong, X; Song, X; Wang, C; Wang, L; Wang, W; Wang, X; Wu, H; Xu, H; Zhao, L | 1 |
| Li, Y; Liu, M; Wang, Z; Zhao, Y; Zheng, Y | 1 |
| Augu-Denechere, D; Bonnin, N; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Péron, J; Puszkiel, A; Rousset, P; Tartas, S; Tod, M; Trillet-Lenoir, V; You, B | 1 |
| Aisner, J; Cerchio, R; Chan, N; Chen, S; Ganesan, S; Goodin, S; Gounder, M; Li, J; Lin, H; Malhotra, J; Marinaro, C; Mehnert, JM; Portal, DE; Shih, W; Silk, AW; Spencer, KR; Stein, MN | 1 |
| He, Z; Kong, Z; Li, S; Luo, C; Sun, J; Wang, Z; Ye, H; Zhang, S; Zheng, Y | 1 |
| Alvarez-Ramirez, M; Díaz-Cedillo, F; Figueroa-Valverde, L; López-Gutierrez, T; López-Ramos, M; Mateu-Armad, MV; Rosas-Nexticapa, M | 1 |
| Eisenblätter, M; Faber, C; Gerwing, M; Geyer, C; Hansen, U; Heindel, W; Helfen, A; Hoerr, V; Hoffmann, E; Höltke, C; Karst, U; Krähling, T; Kronenberg, K; Masthoff, M; Maus, B; Schinner, R; Wachsmuth, L; Wildgruber, M | 1 |
| Ghadi, R; Jain, S; Kuche, K; Patel, M; Yadav, V | 1 |
| Fang, M; He, Z; Huang, P; Lei, J; Li, L; Luo, C; Sun, X; Wu, Z; Zhang, S; Zhou, B | 1 |
| Ahmed, EM; El-Dash, Y; Gowifel, AMH; Hassan, MSA; Hassanin, SO; Khalil, NA | 1 |
| Booth, LA; Dent, P; Roberts, JL | 1 |
| Gu, D; He, J; Jin, H; Lv, Y; Qin, W; Sun, J; Sun, L; Wan, J; Wang, C; Wang, H; Wang, S; Wu, H; Yang, C; Yao, M; Yu, C; Zhang, Z | 1 |
| Chen, D; Fu, J; Hu, H; Li, W; Xin, X | 1 |
| Bruce, JN; Buonanno, M; Canoll, PD; Chaudhary, KR; Cheng, SK; Dovas, A; Harken, AD; Hei, TK; Higgins, DM; Kinslow, CJ; Stockwell, BR; Tan, H; Upadhyayula, PS; Wang, TJC; Ye, LF; Zandkarimi, F; Zhang, Y | 1 |
| Cao, Z; Guan, Q; Guo, R; Huang, S; Liu, J; Shuai, X; Wang, Z; Yang, X; Zhang, F | 1 |
| Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
| Chang, WT; Feng, YH; Lee, K; Liu, PY; Wu, SN | 1 |
| Correia, A; Khan, MM; Li, W; Madni, A; Rahim, MA; Santos, HA; Tahir, N | 1 |
| Honeywell, RJ; Mammatas, LH; Menke-van der Houven van Oordt, CW; Peters, GJ; Rovithi, M; Swart, EL; Verheul, HMW; Zandvliet, AS | 1 |
| Alswah, M; El-Adl, K; Nasser, M; Sakr, H; Shoman, FMA | 1 |
| Gan, B; Koppula, P; Zhuang, L | 1 |
| Alpdemir, Ş; Bayram, C; Denkbaş, EB; Haberal, E; Kara, G; Vural, T | 1 |
| Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G | 2 |
| Chou, CW; Huang, YK; Kuo, TT; Liu, JP; Sher, YP | 1 |
| Amaria, RN; Call, SG; Falchook, GS; Holley, VR; Hong, DS; Huang, HJ; Janku, F; Kato, S; Meric-Bernstam, F; Naing, A; Patel, SP; Piha-Paul, SA; Sakamuri, D; Tsimberidou, AM; Zinner, RG | 1 |
| Afify, SM; Atallah, MN; Hassan, G; Nawara, HM; Seno, A; Seno, M; Zahra, MH | 1 |
| Bhattacharya, SK; Galav, V; Gupta, R; Jain, S; Kumar, M; Meshram, GG; Prasad, A; Rastogi, T; Sharma, S | 1 |
| Cai, N; Cheng, K; Liang, H; Wen, J; Xiong, Y; Zhang, W; Zhang, Y; Zhu, J | 1 |
| Balalaeva, IV; Krysko, DV; Mishchenko, TA; Vedunova, MV | 1 |
| Abulkhair, HS; El-Adl, K; El-Hddad, SSA; El-Helby, AA; Nasser, M; Sakr, H | 1 |
| Cui, X; Han, L; Li, Y; Liu, Y; Song, B; Sun, W; Wang, H; Zhang, Y; Zhou, W | 1 |
| Bruchard, M; Geindreau, M; Ghiringhelli, F | 1 |
| Conrad, M; Mishima, E; Proneth, B; Sato, H; Sato, M; Zheng, J | 1 |
| Cheng, HJ; Chu, YY; Li, G; Li, WB; Sun, CJ; Tian, ZH; Zhao, JC | 1 |
| Altman, RB; Giacomini, C; Giacomini, MM; Gong, L; Klein, TE; Maitland, ML | 1 |
| Brade, A; Chung, C; Dawson, L; Longo, J; Milosevic, M; Murray, L; Oza, A; Wan, J; Wang, L | 1 |
| Covell, DG | 1 |
| Bruner, JK; Jones, RJ; Levis, MJ; Li, L; Ma, HS; Pratilas, CA; Pratz, KW; Qin, ACR; Rudek, MA; Small, D | 1 |
| Fujii, H; Hamamichi, S; Hori, Y; Ito, K; Matsui, J; Ozawa, Y; Umeda, IO | 1 |
| Bao, R; Gao, L; Jia, B; Lai, J; Liu, Z; Lu, D; Wang, F; Wang, Y; Yang, Z; Zhang, C; Zhao, Y; Zhu, H | 1 |
| Eucker, J; Gomez-Roca, C; Graudenz, K; Huang, F; Lettieri, J; Marmé, F; Peña, C; Trnkova, ZJ | 1 |
| Chi, H; Meng, Z; Wang, H; Zhang, C | 1 |
| Dekker, H; Labots, M; Meijer, GA; Pham, TV; Ruijter, R; Van der Hoeven, JJM; Van der Mijn, JC; Van der Vliet, HJ; Verheul, HMW | 1 |
| Angelidakis, G; Hosry, J; Jiang, Y; Kaseb, A; Torres, HA | 1 |
| Fuss, H; Jung, S; Lademann, J | 1 |
| Abedi Karjiban, R; Basri, M; Fard Masoumi, HR; Izadiyan, Z; Kalantari, K; Salim, N | 1 |
| Dai, C; Shao, JH; Wu, LQ; Yin, XB; Yu, X; Zhou, F | 1 |
| Kang, R; Liu, J; Tang, D; Wen, Q; Zhou, B | 1 |
| Cai, J; Gao, Q; Han, Y; Hezam, K; Jiang, J; Liu, Y; Sun, F; Wang, M; Wang, T; Xie, J; Zhang, J; Zhang, X | 1 |
| Gyawali, B; Kesselheim, AS | 1 |
| Christen, KE; Davis, RA; Kennedy, D | 1 |
| Chen, C; Feng, X; Liu, J; Tang, J; Yan, J; Zeng, Z | 1 |
| Eriksson, J; Hendrikse, NH; Poot, AJ; Rongen, M; Schuit, RC; Stigter-van Walsum, M; van der Wildt, B; van Dongen, GA; Windhorst, AD | 1 |
| Funakoshi, T; Galsky, MD; Latif, A | 1 |
| Bedikian, AY; Falchook, G; Fu, S; Ganesan, P; Hong, DS; Janku, F; Kies, M; Kurzrock, R; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Wolff, RA | 1 |
| Baker, SD; Cai, X; Chen, Z; Christensen, R; Inaba, H; Li, L; Navid, F; Regel, J | 1 |
| Prado, CM | 1 |
| Adjei, AA; Bible, KC; Croghan, G; Erlichman, C; Jett, J; Kaufmann, SH; Kumar, SK; Markovic, SN; Marks, R; Molina, J; Moynihan, T; Qin, R; Quevedo, F; Richardson, R; Tan, A | 1 |
| Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE | 1 |
| Baracos, VE; Maia, YL; Ormsbee, M; Prado, CM; Sawyer, MB | 1 |
| Cormode, DP; Farokhzad, OC; Fayad, ZA; Gianella, A; Kim, Y; Labarre, MP; Langer, R; Mieszawska, AJ; Mulder, WJ; Ozcan, C; Petrov, A; Priem, B; van Rooy, I | 1 |
| Armand, JP; de Baere, T; Dessen, P; Lassau, N; Lazar, V; Le Berre, MA; Loriot, Y; Massard, C; Meurice, G; Peña, C; Robert, C; Robert, T; Soria, JC | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; El-Deiry, WS; Goldenberg, D; Humphreys, R; Liu, YY; Smith, CD | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Airaksinen, AJ; Hirvonen, JT; Kaasalainen, MH; Liu, D; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarparanta, MP; Wang, CF | 1 |
| Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B | 1 |
| Chow, S; Gutierrez, JO; Karovic, S; Karrison, TG; Kistner-Griffin, E; Maitland, ML; Thomeas, V; Wroblewski, K | 1 |
| He, J; Li, YS; Wei, LX; Wei, X; Xu, F; Yu, FF; Zhang, TY; Zhang, XJ | 1 |
| Choi, Y; Hur, DY; Kim, D; Kim, YS; Lee, HK; Park, GB | 1 |
| Feng, L; Liu, T; Liu, Y; Wang, L; Yao, Y; Yu, D; Zhang, L; Zhang, N | 1 |
| Chen, Y; Li, J; Li, W; Liu, X; Wan, J; Yu, C | 1 |
| Chen, J; Guo, H; Li, S; Li, Y; Liang, X; Meng, H; Shi, B; Zhang, D; Zhu, Y | 1 |
| Bakris, GL; Cohen, EE; Fleming, GF; House, LK; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; Ratain, MJ; Rudek, MA; Thomeas, V; Wen, Y; Wright, JJ; Wu, K | 1 |
| Abdel-Rahman, O; Fouad, M | 2 |
| Barberis, M; Brunelli, V; Catania, C; Dal Zotto, L; Danesi, R; de Braud, F; De Pas, T; Delmonte, A; Diena, T; Fumagalli, C; Noberasco, C; Rampinelli, C; Santarpia, M; Spitaleri, G; Toffalorio, F; Vecchio, F; Zangarini, M; Zucchetti, M | 1 |
| de Vos, R; Koldenhof, JJ; Teunissen, SC; Tillier, CN; Verheul, HM; Walraven, M; Witteveen, PO | 1 |
| Alexandre, J; Blanchet, B; Boissier, E; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Vidal, M | 1 |
| Hasskarl, J | 2 |
| Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A | 1 |
| Chandran, CB; Flombaum, CD; Glezerman, IG; Salvatore, SP; Seshan, SV; Usui, J | 1 |
| Adjei, AA; Chai, F; Dy, GK; Goff, L; Lamar, M; Ma, WW; Martell, R; Means-Powell, JA; Puzanov, I; Saif, MW; Santoro, A; Savage, RE; Schwartz, B; Simonelli, M; Sosman, J; Zucali, P | 1 |
| Binder, H; Elsäßer, A; Schmidtmann, I; Weinmann, A | 1 |
| Falchook, GS; Fu, S; Hong, DS; Huang, M; Janku, F; Jiang, Y; Kurzrock, R; Lin, Q; Naing, A; Parkhurst, K; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Baert, M; Chauffert, B; Diouf, M; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Saidak, Z | 1 |
| Adjei, AA; Brady, W; DePaolo, D; Ding, Y; Dy, GK; Fetterly, G; Ma, WW; Ngamphaiboon, N; Reungwetwattana, T; Zhao, Y | 1 |
| Gao, ZH; Li, Y; Qu, XJ | 1 |
| Airaksinen, AJ; Hirvonen, JT; Hyvönen, ML; Laakkonen, PM; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarparanta, MP; Wang, CF | 1 |
| Booth, L; Chuckalovcak, J; Cruickshanks, N; Dent, P; Hamed, HA; Poklepovic, A; Roberts, JL; Tavallai, M | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A | 1 |
| Booth, L; Cruz-Luna, T; Cycon, KA; Dent, P; Doern, CD; Fidanza, A; Nourbakhsh, A; Plamondon, P; Roberts, JL; Siembida, P; Smith, E; Tavallai, M | 1 |
| Barrois, C; Berger, F; Cassier, P; El-Madani, M; Freyer, G; Guitton, J; Hénin, E; Lachuer, J; Lefort, T; Rodriguez-Lafrasse, C; Slimane, K; Tod, M; Valette, PJ; You, B | 1 |
| Brzózka, K; Mikula, M; Rzymski, T; Wiklik, K | 1 |
| Brown, JM; Chang, DT; Deng, L; Giaccia, A; Koong, AC; Le, QT; Loo, BW; Pai, RK; Pollom, EL; Shultz, DB | 1 |
| Bessarabova, M; Dorner, A; Gulbekyan, G; Hope, A; Kolpakova-Hart, E; Li, B; Merberg, D; Nikolsky, Y; Pustovalova, O; Schu, M; Shin, H; Trepicchio, WL | 1 |
| Cheng, X; Cheng, Y; Kuang, Y; Pan, X; Yang, X | 1 |
| Nishio, K; Togashi, Y | 1 |
| Gemma, A; Miyanaga, A | 1 |
| Ali, SM; Chmielecki, J; Chudnovsky, J; Elvin, JA; Gay, L; Gray, A; Johnson, A; Lipson, D; Miller, VA; Nakamura, BN; Roels, S; Ross, JS; Stephens, PJ; Vergilio, JA; Wang, K; Wong, MK; Yelensky, R | 1 |
| Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A | 1 |
| Bandukwala, H; Belsúe, V; Casares, N; Coffer, PJ; Durántez, M; Gorraiz, M; Hervás-Stubbs, S; Lasarte, JJ; Lourenço, AR; Lozano, T; Oyarzábal, J; Prieto, J; Riezu-Boj, JI; Ruiz, M; Sarobe, P; Villanueva, L | 1 |
| Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT | 1 |
| Caracciolo, J; Gill, J; Goldberg, J; Hale, GA; Isakoff, MS; Juan, TH; Lee, JK; Lush, RM; Manning, K; Mascarenhas, L; Neuger, AM; Reed, DR; Sandler, E; Smith, T; Sullivan, DM | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM | 1 |
| Jaffry, A; Jean, GW; Khan, SA; Mani, RM | 1 |
| Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R | 1 |
| Delhaas, T; Gagliardi, M; Grandfils, C; Knetsch, ML; Koole, LH; Molin, DG; Sevrin, C; van den Akker, NM; Wang, Y | 1 |
| Kim, HR; Kim, JH; Kim, S; Kwack, K; Lee, MG; Lim, SM; Moon, YW; Park, HS | 1 |
| Amadori, D; Bianchini, E; Casadei Gardini, A; Frassineti, GL; Gallani, ML; Masini, C; Maugeri, A; Menozzi, S; Minguzzi, M; Nanni, O; Palazzini, S; Restuccia, S; Scarpi, E; Tenti, E; Valgiusti, M | 1 |
| Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W | 1 |
| Fergusson, D; Henderson, VC; Kimmelman, J; MacKinnon, N; Mattina, J | 1 |
| Durmus, S; Schinkel, AH; van Hoppe, S | 1 |
| Ando, M; Ando, Y; Gyawali, B; Honda, K; Shimokata, T | 1 |
| Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M | 1 |
| Fritz, C; Guckenberger, M; Hoyer, M; Kroeze, SG; Lo, SS; Ricardi, U; Sahgal, A; Stahel, R; Stupp, R | 1 |
| Badary, OA; Barrois, C; Cassier, P; Colomban, O; El-Demerdash, E; El-Madani, M; El-Shenawy, SM; Freyer, G; Gagnieu, MC; Guitton, J; Hommel-Fontaine, J; Ibrahim, BM; Lefort, T; Maillet, D; Peron, J; Rodriguez-Lafrasse, C; Tod, M; Valette, PJ; You, B | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Carlisle, B; Fergusson, D; Hachem, Y; Kimmelman, J; Mattina, J | 1 |
| Alivon, M; Boutouyrie, P; De Lepper, AG; Delhaas, T; Giroux, J; Goldwasser, F; Reesink, KD; Spronck, B | 1 |
| Heinemann, V; Stemmler, HJ | 1 |
| Del Conte, G; Guibal, A; Rüegg, C; Sessa, C | 1 |
| Chen, EX; Ng, R | 1 |
| Cannistra, SA | 1 |
| Annunziata, CM; Azad, NS; Cao, L; Chen, HX; Chow, C; Figg, WD; Jain, L; Kohn, EC; Kotz, HL; Kwitkowski, VE; McNally, D; Minasian, L; Posadas, EM; Premkumar, A; Sarosy, G; Steinberg, SM; Wright, JJ | 1 |
| Awada, A; D'Hondt, V; Dal Lago, L | 1 |
| Curiel, DT; Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Lee, R; Martin, AP; Mitchell, C; Park, MA; Rahmani, M; Roberts, JD; Yacoub, A; Zhang, G | 1 |
| Alexandrescu, DT; Anderson, RT; Atkins, MB; Dutcher, JP; Garbe, C; Guitart, J; Hauschild, A; Kong, HH; Lacouture, ME; Puzanov, I; Robert, C; Wood, L; Wu, S | 1 |
| Lenihan, DJ | 1 |
| Escudier, B; Mateus, C; Robert, C; Spatz, A; Wechsler, J | 1 |
| Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT | 1 |
| Kung, EF; Maddox, JS; Petronic-Rosic, V; Sethi, A | 1 |
| Abou-Alfa, G; Dees, EC; Desai, A; Edelman, MJ; Fakih, MG; Frank, RC; Hohl, RJ; Hollis, DR; Hwang, J; Kennedy, EB; Lewis, LD; Millard, F; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA | 1 |
| Benichou, AS; Billemont, B; Blanchet, B; Chhun, S; Cramard, J; Dauphin, A; Goldwasser, F; Harcouet, L; Ropert, S; Tod, M | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F | 1 |
| Maitland, ML; Snider, KL | 1 |
| Chen, MH | 1 |
| Cheung, YK | 1 |
| Billemont, B; Kelly, RJ; Rixe, O | 1 |
| Shibuya, M | 1 |
| English, BC; Figg, WD; Price, DK | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Brower, V | 1 |
| Cortés-Funes, H | 1 |
| Crowley, J; Leblanc, M; Rankin, C | 1 |
| Kong, HH; Turner, ML | 1 |
| Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L | 1 |
| Carlo-Stella, C; Giacomini, A; Gianni, AM; Lavazza, C; Righi, M; Sia, D | 1 |
| Ivy, SP; Kaufman, BM; Wick, JY | 1 |
| Black, HR; Elliott, WJ; Karrison, T; Kasza, KE; Maitland, ML; Moshier, K; Ratain, MJ; Sit, L; Stadler, WM; Undevia, SD | 1 |
| Atkins, MB; Humphreys, BD | 1 |
| Boere, IA; Hamberg, P; Sleijfer, S | 1 |
| Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L | 1 |
| Wang, ZY | 1 |
| Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Minor, DR | 1 |
| Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA | 1 |
| Bandarchi-Chamkhaleh, B; Chen, EX; Do, T; Duran, I; Le Tourneau, C; MacLean, M; Mak, TW; Metser, U; Nayyar, R; Pham, NA; Quintela-Fandino, M; Siu, LL; Tsao, M; Tusche, MW; Wang, L; Wright, JJ | 1 |
| Alter, M; Degen, A; Gutzmer, R; Kapp, A; Satzger, I; Schenck, F; Völker, B | 1 |
| Appleman, LJ; Cihon, F; Mazzu, A; Mita, AC; Shapiro, GI; Sundaresan, PR; Tolcher, AW | 1 |
| Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O | 1 |
| Sato, Y | 1 |
| Brandes, AA; Franceschi, E; Girardi, F | 1 |
| Eto, M; Itsumi, M; Naito, S; Shiota, M; Tada, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A | 1 |
| Baum, CE; Dahut, WL; Danesi, R; English, BC; Figg, WD; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Liewehr, D; Price, DK; Sissung, TM; Venitz, J; Venzon, D; Yarchoan, R | 1 |
| Eames, T; Staehler, M; Wollenberg, A | 1 |
| Udagawa, T; Wood, M | 1 |
| Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Watkins, A | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC | 1 |
| Avril, MF; Barete, S; Billemont, B; Blanchet, B; Carlotti, A; Francès, C; Franck, N; Goldwasser, F; Moguelet, P; Ropert, S | 1 |
| Hoshida, Y; Newell, P; Villanueva, A | 1 |
| Burger, DM; Desar, IM; Timmer-Bonte, JN; van der Graaf, WT; van Herpen, CM | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Bhujanga Rao, AK; Pulla Reddy, M; Ravikumar, K; Sridhar, B | 1 |
| Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N | 1 |
| Katsahian, S; O'Quigley, J; Zohar, S | 1 |
| Gong, P; Li, G; Li, W; Pu, Y; Zhai, X; Zhong, Z | 1 |
| Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K | 1 |
| Ma, L; Wang, Y; Wu, Z; Zhang, L; Zhou, Q | 1 |
| Kumar, B; Kumar, P; Teknos, TN; Yadav, A | 1 |
| Geoerger, B; Leblond, P | 1 |
| Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A | 1 |
| Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA | 1 |
| Caponigro, F; Ciarmiello, A; Milano, A; Perri, F | 1 |
| Abbas, H; Bancelin, N; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Ropert, S; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
| Cui, Z; He, B; Qu, W; Wang, JC; Wang, YB; Zhang, H; Zhang, JY; Zhang, Q | 1 |
| Curtit, E; Le Tourneau, C; Mansi, L; Medioni, J; Viel, E | 1 |
| Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y | 1 |
| Abbas, H; Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Goldwasser, F; Harcouet, L; Hornecker, M; Mir, O; Ropert, S; Sassi, H; Taieb, F; Tod, M | 1 |
| Fukushima, H; Gao, D; Inuzuka, H; Lau, AW; Liu, P; Wan, L; Wang, Z; Wei, W | 1 |
| Beckett, L; Eddings, C; Gandara, D; Lara, PN; Lau, DH; Pan, CX; Semrad, TJ | 1 |
| Reed, MW; Young, RJ | 1 |
| Pratz, KW; Rudek, MA; Smith, BD; Villarroel, MC; Wright, JJ; Xu, L | 1 |
| André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J | 1 |
| Heuer, V; Kummer, G; Neumann, H; Roy, R; Schultheis, B; Strumberg, D | 1 |
| Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S | 1 |
| Allavena, P; Mantovani, A | 1 |
| Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M | 1 |
| Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R | 1 |
| Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA | 1 |
| Ibrahim, N; Walsh, WR; Yang, JL; Yu, Y | 1 |
| Chiang, IT; Hsu, FT; Hwang, JJ; Liu, YC | 1 |
| Döme, B; Török, S | 1 |
| Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
| Basu, B; Kaye, SB; Molife, LR; Moreno Garcia, V | 1 |
| Dong, Z; Nör, JE; Zeitlin, BD | 1 |
| Billemont, B; Blanchet, B; Boudou-Rouquette, P; Cabanes, L; Coriat, R; Franck, N; Goldwasser, F; Mir, O; Ropert, S; Tod, M | 1 |
| Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Loriot, MA; Mir, O; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
| Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Gao, PT; Han, BH; Li, GL; Li, HJ; Ma, J; Mao, WF; Shao, MH; Yuan, CG | 1 |
| Adamson, PC; Balis, FM; Baruchel, S; Blaney, SM; Burke, M; Fox, E; Glade Bender, J; Ingle, AM; Kim, A; Stempak, D; Weigel, B; Widemann, BC | 1 |
| Bottai, G; Santarpia, L | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP | 1 |
| Baker, SD; Billups, CA; Davidoff, AM; Fofana, D; Furman, WL; Hu, S; Leung, W; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Reddick, WE; Santana, VM; Spunt, SL; Stewart, CF; Turner, D; Wu, J | 1 |
| Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M | 1 |
| Chen, J; Sun, W; Xu, WF; Yao, JW | 1 |
| Baker, SD; Gibson, AA; Hu, S; Li, L; Orwick, SJ; Roberts, JL; Sparreboom, A; Zimmerman, EI | 1 |
| Rose, S | 1 |
| Hirte, HW; Hotte, SJ | 1 |
| Chien, DS; Wilhelm, S | 1 |
| Beling, C; Hilger, RA; Kredtke, S; Moeller, JG; Richly, H; Scheulen, ME; Seeber, S; Strumberg, D; Voliotis, D | 1 |
| Beeram, M; Patnaik, A | 1 |
| Lee, JT; McCubrey, JA | 1 |
| Grubert, M; Hilger, RA; Kredtke, S; Kupsch, P; Passage, K; Richly, H; Scheulen, ME; Seeber, S; Strumberg, D; Voliotis, D | 1 |
| Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D | 1 |
| Bollag, G; Freeman, S; Lyons, JF; Post, LE | 1 |
| Hilger, RA; Kredtke, S; Scheulen, ME; Seeber, S; Strumberg, D | 1 |
| Seeber, S; Strumberg, D | 1 |
| Awada, A; Bartholomeus, S; Brendel, E; de Valeriola, D; Gil, T; Haase, CG; Hendlisz, A; Mano, M; Piccart, M; Schwartz, B; Strumberg, D | 1 |
| Marx, J | 1 |
| Gravell, A; Wright, JJ; Zerivitz, K | 2 |
| Lyons, J; Thompson, N | 1 |
| Armand, JP; Boige, V; Escudier, B; Le Cesne, A; Le Chevalier, T; Lhomme, C; Malka, D; Pautier, P; Robert, C; Soria, JC; Spatz, A; Wechsler, J | 1 |
| Cihon, F; Hirte, HW; Hotte, SJ; Lathia, C; Moore, M; Oza, A; Petrenciuc, O; Schwartz, B; Siu, L | 1 |
| Clark, JW; Eder, JP; Lathia, C; Lenz, HJ; Ryan, D | 1 |
| Beeram, M; Patnaik, A; Rowinsky, EK | 2 |
| Soff, G; Zakarija, A | 1 |
| Awada, A; Giannaris, T; Lathia, C; Moore, MJ; Petrenciuc, O; Piccart, M; Schwartz, B; Siu, LL; Takimoto, CH | 1 |
| Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D | 1 |
| Flaherty, KT; Gallagher, M; Mosenkis, A; O'Dwyer, PJ; Stevenson, JP; Townsend, RR; Veronese, ML | 1 |
| Chow, S; Hedley, D; Tong, FK | 1 |
| Brendel, E; Christensen, O; Flashar, C; Grubert, M; Henning, BF; Hilger, RA; Kupsch, P; Ludwig, M; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R | 1 |
| Frantz, S | 1 |
| Budillon, A; Caraglia, M; Marra, M; Tagliaferri, P; Tassone, P; Venuta, S | 1 |
| McCormick, F; Oda, K; Okada, J; Rauen, K; Rodriguez-Viciana, P; Tetsu, O | 1 |
| Carter, C; Gollob, JA; Kelley, SL; Wilhelm, S | 1 |
| Rapp, UR; Schreck, R | 1 |
| Curtiss, FR | 1 |
| Carter, C; Dumas, J; Kelley, S; Lowinger, T; Lynch, M; Schwartz, B; Simantov, R; Smith, RA; Wilhelm, S | 1 |
| Burton, A | 1 |
| Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D | 1 |
| Arslan, MA; Basaga, H; Kutuk, O | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A | 1 |
| Awada, A; Clark, JW; Eder, JP; Hendlisz, A; Hirte, HW; Lenz, HJ; Moore, MJ; Richly, H; Schwartz, B; Strumberg, D | 1 |
| Senan, S; Smit, EF | 1 |
| Flaherty, KT | 1 |
| Kamba, T; McDonald, DM | 1 |
| Batt, D; Li, N; Warmuth, M | 1 |
| Kibble, A; Shumoogam, J | 1 |
| Chen, EX; Dancey, J; Duan, L; Duran, I; Hirte, H; Hotté, SJ; Lathia, C; MacLean, M; Pond, GR; Siu, LL; Turner, S; Walsh, S; Wright, JJ | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Faivre, S; Le Tourneau, C; Raymond, E | 1 |
| Awada, A; Takimoto, CH | 1 |
| Claflin, JE; Crean, S; Lahn, M; Linz, H; Noel, JK; Ranganathan, G | 1 |
| Chu, D; Fillos, T; Lacouture, ME; Wu, S | 1 |
| Chen, JJ; Kudelka, A; Lu, J; Wu, S; Zhu, X | 1 |
| Tuma, RS | 1 |
| Rini, BI | 1 |
| Giordano, S; Petrelli, A | 1 |
| El-Deiry, WS; Kim, SH; Ricci, MS | 1 |
| Araki, K; Ebi, H; Kawada, K; Kim, YI; Kitagawa, K; Minami, H; Mukai, H; Nakajima, H; Nakajima, K; Tahara, M | 1 |
128 review(s) available for sorafenib and Neoplasms
| Article | Year |
|---|---|
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries | 2015 |
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Topics: Antineoplastic Agents; Cyclin-Dependent Kinase 8; Cytokines; Humans; Male; Molecular Targeted Therapy; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Transcription Factors; Tumor Escape | 2018 |
Current Insights of BRAF Inhibitors in Cancer.
Topics: Animals; Drug Discovery; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2018 |
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Humans; MAP Kinase Signaling System; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; raf Kinases | 2018 |
CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
Topics: Colorectal Neoplasms; Cyclin-Dependent Kinase 8; Drug Discovery; Humans; Mediator Complex; Molecular Structure; Neoplasms; Oncogenes; Protein Kinase Inhibitors; Wnt Signaling Pathway | 2019 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Tetrazoles as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tetrazoles | 2020 |
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Development; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret | 2021 |
Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.
Topics: Acridines; Acriflavine; Anti-Bacterial Agents; COVID-19 Drug Treatment; Humans; Intercalating Agents; Neoplasms; SARS-CoV-2 | 2022 |
Progress in Application of Nanotechnology in Sorafenib.
Topics: Biological Availability; Humans; Nanotechnology; Neoplasms; Solubility; Sorafenib | 2021 |
KDR genetic predictor of toxicities induced by sorafenib and regorafenib.
Topics: Humans; Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Topics: Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Neoplasms; Pyridoxine; Randomized Controlled Trials as Topic; Sorafenib | 2022 |
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Endothelial Cells; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Mice; Neoplasms; Neovascularization, Pathologic; Sorafenib | 2022 |
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib.
Topics: Animals; Apoptosis; Autophagy; Cell Survival; Humans; Neoplasms; Quinolines; Signal Transduction; Sorafenib | 2020 |
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Cystine; DNA Methylation; Ferroptosis; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glutathione; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Piperazines; Signal Transduction; Sorafenib; Sulfasalazine | 2021 |
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges.
Topics: Cachexia; Humans; Molecular Targeted Therapy; Multicenter Studies as Topic; Muscle, Skeletal; Neoplasms; Nutrition Assessment; Nutritional Status; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Randomized Controlled Trials as Topic; Recommended Dietary Allowances; Sorafenib; Sunitinib; Treatment Outcome | 2020 |
An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases.
Topics: ADAM Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Neoplasms; Neurodegenerative Diseases; Phenylurea Compounds; Pyridines; Retinal Diseases; Sorafenib; Tumor Microenvironment | 2020 |
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors.
Topics: Acetaminophen; Antineoplastic Agents; Antioxidants; Apoptosis; Artemisinins; Auranofin; Cell Death; Cisplatin; Epigenesis, Genetic; Fatty Acids; Ferroptosis; Haloperidol; Humans; Indoles; Iron; Lapatinib; Mevalonic Acid; NADP; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxygen; Quinolines; Reactive Oxygen Species; Sorafenib; Spiro Compounds; Sulfasalazine; Trigonella | 2020 |
Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.
Topics: Adaptive Immunity; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Capillary Permeability; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Immunologic Factors; Neoplasms; Neovascularization, Pathologic; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2021 |
PharmGKB summary: sorafenib pathways.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Gene Regulatory Networks; Humans; Neoplasms; Niacinamide; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenylurea Compounds; Sorafenib | 2017 |
Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Hemorrhage; Humans; Incidence; Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Blood Pressure; Chi-Square Distribution; Drug Administration Schedule; Humans; Hypertension; Incidence; Molecular Targeted Therapy; Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Severity of Illness Index; Sorafenib; Time Factors | 2013 |
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Niacinamide; Nutritional Status; Nutritional Support; Phenylurea Compounds; Sorafenib | 2013 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
Risk of treatment-related mortality with sorafenib in patients with cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate | 2014 |
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy; Humans; Hypertension; Incidence; Kidney Neoplasms; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome | 2014 |
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; Hand-Foot Syndrome; Humans; Incidence; Mucositis; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk; Sorafenib | 2014 |
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Topics: Antineoplastic Agents; Case Management; Drug Interactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Assessment; Sorafenib | 2014 |
Sorafenib: targeting multiple tyrosine kinases in cancer.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Retrospective Studies; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2014 |
The adverse effects of sorafenib in patients with advanced cancers.
Topics: Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Topics: Animals; Antineoplastic Agents; Biological Transport; Glucuronides; Glucuronosyltransferase; Humans; Liver; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Tissue Distribution | 2015 |
CDK8 kinase--An emerging target in targeted cancer therapy.
Topics: Cyclin-Dependent Kinase 8; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Transcription, Genetic | 2015 |
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Gastrointestinal Tract; Humans; Intestine, Small; Neoplasms; Neovascularization, Pathologic; Niacinamide; Organs at Risk; Phenylurea Compounds; Radiosurgery; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2015 |
Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
Topics: Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib | 2015 |
[Kinase inhibitors and their resistance].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib | 2015 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Topics: Antineoplastic Agents; Carcinoma; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2016 |
Antiangiogenic therapy in oncology: current status and future directions.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Neoplasms; Niacinamide; Phenylurea Compounds; Research Design; Sorafenib | 2016 |
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids | 2016 |
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Risk; Sorafenib | 2017 |
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; CTLA-4 Antigen; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Radiosurgery; Sorafenib | 2017 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Confidence Intervals; Humans; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Survival Analysis | 2017 |
[Oncology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Sorafenib (BAY 43-9006): review of clinical development.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Design; Drug Therapy, Combination; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib | 2006 |
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Thyroid Function Tests; Treatment Outcome | 2009 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
The role of antiangiogenesis therapy: bevacizumab and beyond.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
An overview of small-molecule inhibitors of VEGFR signaling.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cadherins; Clinical Trials, Phase III as Topic; Extracellular Matrix Proteins; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; National Cancer Institute (U.S.); Neoplasms; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Structure-Activity Relationship; Sunitinib; Transcription Factors; United States | 2009 |
It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Compounds in clinical Phase III and beyond.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2010 |
The hand-foot-syndrome associated with medical tumor therapy - classification and management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
[Anti-angiogenic drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Hypoxia-Inducible Factor 1; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib | 2010 |
Tumor-stromal cell interactions and opportunities for therapeutic intervention.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cell Communication; Endothelial Cells; Fibroblasts; Humans; Mesenchymal Stem Cells; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Stromal Cells | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Genetic Predisposition to Disease; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Population Surveillance; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome; United States | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Meta-analysis of dermatological toxicities associated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Skin Diseases; Sorafenib | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Targeted-therapy and imaging response: a new paradigm for clinical evaluation?
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
[Targeting the RAS signalling pathway in cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib | 2011 |
The two faces of FBW7 in cancer drug resistance.
Topics: Amyloid Precursor Protein Secretases; Apoptosis; Benzenesulfonates; Biphenyl Compounds; Cell Cycle Proteins; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MAP Kinase Signaling System; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Niacinamide; Nitrophenols; Paclitaxel; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Sulfonamides; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination; Vincristine | 2011 |
Anti-angiogenic therapy: concept to clinic.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Humans; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Using NF-κB as a molecular target for theranostics in radiation oncology research.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Radiation Oncology; Radiation Tolerance; Signal Transduction; Sorafenib | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Combining antiangiogenics to overcome resistance: rationale and clinical experience.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
[Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship | 2012 |
BAY 43-9006: early clinical data in patients with advanced solid malignancies.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2002 |
BAY 43-9006: preclinical data.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Disease Progression; Humans; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2002 |
Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
Topics: Adult; Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Child; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Neoplasm Proteins; Neoplasms; Niacinamide; Oligodeoxyribonucleotides, Antisense; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Thionucleotides; Xenograft Model Antitumor Assays | 2002 |
BAY-43-9006 Bayer/Onyx.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drugs, Investigational; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Technology, Pharmaceutical | 2003 |
Raf pathway inhibitors in oncology.
Topics: Animals; Benzenesulfonates; Enzyme Inhibitors; Humans; MAP Kinase Signaling System; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2003 |
Raf kinase inhibitors in oncology.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib | 2005 |
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Topics: Animals; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2005 |
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Topics: Antibodies, Blocking; Antineoplastic Agents; Benzamides; Benzenesulfonates; ErbB Receptors; Hair Diseases; Humans; Imatinib Mesylate; Nail Diseases; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Skin Diseases; Sorafenib | 2005 |
Raf: a strategic target for therapeutic development against cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Down-Regulation; Drug Delivery Systems; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Biology; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sensitivity and Specificity; Signal Transduction; Sorafenib | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Regulation of c-Raf-1: therapeutic implications.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Niacinamide; Oligodeoxyribonucleotides, Antisense; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Thionucleotides | 2003 |
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Eruptions; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2006 |
Targeting Raf-kinase: molecular rationales and translational issues.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib | 2006 |
Cancer targets in the Ras pathway.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Design; Female; Genes, ras; Humans; Male; Models, Biological; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Signal Transduction; Sorafenib | 2005 |
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Melanoma; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Isoforms; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2006 |
Raf kinases: oncogenesis and drug discovery.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal; Enzyme Inhibitors; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2006 |
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Combinatorial Chemistry Techniques; Drug Design; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2006 |
Protein kinases as drug targets in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab | 2006 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Angiogenesis in cancer: molecular mechanisms, clinical impact.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Humans; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib | 2007 |
Design of clinical trials of radiation combined with antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiation Dosage; raf Kinases; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2007 |
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
B-Raf kinase inhibitors for cancer treatment.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Enzyme Inhibitors; Humans; Imidazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Drug Interactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thalidomide | 2008 |
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions; Foot; Hand; Humans; Incidence; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Risk Factors; Skin; Skin Diseases; Sorafenib | 2008 |
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Incidence; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Mcl-1: a gateway to TRAIL sensitization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2008 |
57 trial(s) available for sorafenib and Neoplasms
| Article | Year |
|---|---|
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Topics: Biomarkers; Everolimus; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Progression-Free Survival; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2023 |
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Maximum Tolerated Dose; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Riluzole; Sorafenib | 2023 |
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study.
Topics: Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pulse Therapy, Drug; Sorafenib; Treatment Outcome | 2020 |
Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2017 |
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Furans; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Salvage Therapy; Sorafenib; Survival Rate; Young Adult | 2018 |
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sorafenib; Thalidomide; Young Adult | 2014 |
Alternative formulations of sorafenib for use in children.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2014 |
Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiopoietin-2; Biomarkers; Exercise; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2014 |
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult | 2014 |
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Sirolimus; Sorafenib | 2014 |
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP2C19; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib; Treatment Outcome; Young Adult | 2015 |
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins; PTEN Phosphohydrolase; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2015 |
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2015 |
Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Everolimus; Humans; Models, Theoretical; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Diphenylamine; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2016 |
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Child; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2016 |
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Niacinamide; Peptides, Cyclic; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2017 |
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Hepatic Insufficiency; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Renal Insufficiency; Sorafenib; Treatment Outcome; Young Adult | 2009 |
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome | 2009 |
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Biomarkers, Pharmacological; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2010 |
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Blood Pressure; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ventricular Function, Left | 2011 |
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease Progression; Female; Humans; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2011 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Saturable absorption of sorafenib in patients with solid tumors: a population model.
Topics: Absorption; Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2012 |
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Tolerance; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sorafenib | 2012 |
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Sorafenib | 2012 |
Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Israel; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vitamin B Complex | 2012 |
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cohort Studies; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Taxoids; Treatment Outcome | 2012 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Leukemia; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult | 2012 |
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib | 2012 |
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2013 |
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
Topics: Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Maximum Tolerated Dose; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2002 |
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Benzenesulfonates; Doxorubicin; Humans; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2003 |
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
Topics: Adult; Area Under Curve; Benzenesulfonates; Diarrhea; Drug Administration Schedule; Exanthema; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2004 |
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Time Factors | 2005 |
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Mechanisms of hypertension associated with BAY 43-9006.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; Benzenesulfonates; CD13 Antigens; CD3 Complex; Drug Monitoring; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Hemolysis; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MAP Kinase Signaling System; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Sorafenib; Stem Cell Factor; Stem Cells; Tetradecanoylphorbol Acetate | 2006 |
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2006 |
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2007 |
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2007 |
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
138 other study(ies) available for sorafenib and Neoplasms
| Article | Year |
|---|---|
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays | 2004 |
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors | 2007 |
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Oxazines; Structure-Activity Relationship | 2011 |
New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship; Thiazoles | 2011 |
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
Topics: Antineoplastic Agents; Apoptosis; Farnesol; Humans; Neoplasms; Salicylates; Signal Transduction | 2014 |
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
Topics: Antineoplastic Agents; Azo Compounds; Benzylidene Compounds; Cell Line, Tumor; Cycloaddition Reaction; Drug Discovery; Humans; Indoles; Models, Molecular; Neoplasms; Oxazolone; Oxindoles; Pyrrolidines; Spiro Compounds; Stereoisomerism; Thiosemicarbazones | 2015 |
Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
Topics: Acylation; Amination; Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors.
Topics: Antineoplastic Agents; Carbazoles; Drug Discovery; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Docking Simulation; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Structure-Activity Relationship | 2017 |
Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.
Topics: Amides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Discovery; fms-Like Tyrosine Kinase 3; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2018 |
Synthesis and anticancer activity of new dihydropyrimidinone derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrimidinones; TOR Serine-Threonine Kinases | 2018 |
Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Immunologic Factors; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Identification of Thieno[3,2-
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 1; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasm Metastasis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiophenes; Xenograft Model Antitumor Assays | 2021 |
A biomimetic nanodrug self-assembled from small molecules for enhanced ferroptosis therapy.
Topics: Animals; Biomimetics; Cell Line, Tumor; Ferroptosis; Mice; Neoplasms; Reactive Oxygen Species; Sorafenib; Tumor Microenvironment | 2022 |
Glutathione Depletion-Induced Activation of Dimersomes for Potentiating the Ferroptosis and Immunotherapy of "Cold" Tumor.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Ferroptosis; Glutathione; Immunotherapy; Mice; Neoplasms; Sorafenib | 2022 |
Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage.
Topics: Amygdalin; Animals; Antioxidants; Ascites; Carcinoma, Ehrlich Tumor; Liver; Matrix Metalloproteinase 9; Mice; Neoplasms; NF-E2-Related Factor 2; Sorafenib; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2022 |
Apigenin alleviates cancer drug Sorafenib induced multiple toxic effects in Swiss albino mice via anti-oxidative stress.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apigenin; Apoptosis; Humans; Mice; Neoplasms; Oxidative Stress; Sorafenib | 2022 |
Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer.
Topics: Amino Acid Transport System y+; Apoptosis; Cell Line, Tumor; Ferroptosis; Humans; Neoplasms; Sorafenib; Triterpenes; Ursolic Acid | 2022 |
Antineoplastic Enzyme as Drug Carrier with Activatable Catalytic Activity for Efficient Combined Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glucose Oxidase; Humans; Hydrogen Peroxide; Nanoparticles; Neoplasms; Paclitaxel; Sorafenib; Tumor Microenvironment | 2022 |
Sorafenib-Loaded Copper Peroxide Nanoparticles with Redox Balance Disrupting Capacity for Enhanced Chemodynamic Therapy against Tumor Cells.
Topics: Cell Line, Tumor; Copper; Glutathione; Humans; Hydrogen Peroxide; Hydroxyl Radical; Lipid Peroxides; Nanoparticles; Neoplasms; Oxidation-Reduction; Peroxides; Povidone; Sorafenib; Tumor Microenvironment | 2022 |
Microfluidic preparation and optimization of sorafenib-loaded poly(ethylene glycol-block-caprolactone) nanoparticles for cancer therapy applications.
Topics: Drug Carriers; Humans; Microfluidics; Nanoparticles; Neoplasms; Particle Size; Polyesters; Polyethylene Glycols; Reproducibility of Results; Sorafenib | 2023 |
Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib.
Topics: Cystine; Drug Resistance, Neoplasm; Ferroptosis; Fusion Regulatory Protein 1, Heavy Chain; Glutathione; Humans; Nanotechnology; Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Sorafenib | 2023 |
Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.
Topics: Animals; Antioxidants; Cell Line, Tumor; Coenzymes; Glutathione; Humans; Hypoxia; Mice; NADP; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Sorafenib | 2023 |
Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication.
Topics: Animals; Humans; Hypoxia; Lighting; Mice; Neoplasms; Sorafenib | 2023 |
Interaction of Some Amino-Nitrile Derivatives with Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) Using a Theoretical Model.
Topics: Humans; Models, Theoretical; Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2023 |
Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
Topics: Albumins; Animals; Cognition; Immunotherapy; Mice; Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Exploring Sorafenib and Simvastatin Combination for Ferroptosis-Induced Cancer Treatment: Cytotoxicity Screening, In Vivo Efficacy, and Safety Assessment.
Topics: Drug Delivery Systems; Early Detection of Cancer; Ferroptosis; HeLa Cells; Humans; Neoplasms; Sorafenib | 2023 |
Self-engineered binary nanoassembly enabling closed-loop glutathione depletion-amplified tumor ferroptosis.
Topics: Animals; Ferroptosis; Glutathione; Lipid Peroxidation; Mice; Neoplasms; Reactive Oxygen Species; Sorafenib | 2023 |
Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity.
Topics: Antineoplastic Agents; Antioxidants; Cell Proliferation; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Niacin; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Superoxide Dismutase; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2023 |
Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; Female; Humans; Hyperthermia, Induced; Indocyanine Green; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Reactive Oxygen Species; Sorafenib | 2019 |
Transferrin-Modified Nanoliposome Codelivery Strategies for Enhancing the Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Humans; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms; Sorafenib; Transferrin | 2020 |
Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis Inducers.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Carbolines; Cell Line, Tumor; Ferroptosis; Gamma Rays; Humans; Imidazoles; Ketones; Lipid Peroxidation; Mice, Nude; Neoplasms; Piperazines; Radiation-Sensitizing Agents; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Mesoporous polydopamine carrying sorafenib and SPIO nanoparticles for MRI-guided ferroptosis cancer therapy.
Topics: Ferric Compounds; Ferroptosis; Indoles; Magnetic Resonance Imaging; Nanoparticles; Neoplasms; Polymers; Sorafenib | 2020 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
Differential Inhibitory Actions of Multitargeted Tyrosine Kinase Inhibitors on Different Ionic Current Types in Cardiomyocytes.
Topics: Action Potentials; Animals; Humans; Ion Channels; Ion Transport; Isoproterenol; Lapatinib; Mice; Myocytes, Cardiac; Neoplasms; Potassium; Potassium Channels; Protein Kinase Inhibitors; Rats; Sodium; Sorafenib | 2020 |
Microfluidic fabrication and characterization of Sorafenib-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Humans; Lecithins; Microfluidic Analytical Techniques; Nanoparticles; Neoplasms; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Sorafenib | 2020 |
5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
Topics: Antineoplastic Agents; Doxorubicin; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Thiazolidinediones; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment.
Topics: Alginates; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Liberation; Electron Spin Resonance Spectroscopy; Ferric Compounds; Hep G2 Cells; Humans; Hyperthermia; In Vitro Techniques; Light; Liver Neoplasms; Magnetics; Magnetite Nanoparticles; Metal Nanoparticles; Mice; Microspheres; Neoplasms; Particle Size; Powders; Scattering, Radiation; Sorafenib; Temperature; X-Ray Absorption Spectroscopy | 2020 |
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Crizotinib; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins B-raf; Sorafenib; Vemurafenib | 2021 |
An assay for cancer stem cell-induced angiogenesis on chick chorioallantoic membrane.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Humans; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Sorafenib | 2021 |
Antiangiogenic activity of zinc and zinc-sorafenib combination using the chick chorioallantoic membrane assay: A descriptive study.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Humans; Neoplasms; Neovascularization, Pathologic; Pilot Projects; Sorafenib; Zinc | 2020 |
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment.
Topics: Animals; Carbolines; Cell Line, Tumor; Chlorophyllides; Ferroptosis; Humans; Mice; Nanoparticle Drug Delivery System; Neoplasms; Photochemotherapy; Photosensitizing Agents; Piperazines; Reactive Oxygen Species; Sorafenib; Treatment Outcome | 2021 |
Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Thiazolidinediones; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, erbB-1; Genetic Heterogeneity; Glyburide; Humans; Lymphocytes, Tumor-Infiltrating; Neoplasms; Phenylurea Compounds; Precision Medicine; Pyridines; Software; Sorafenib; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2021 |
Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; HEK293 Cells; Humans; Mice; Neoplasms; Piperazines; Protein Kinase Inhibitors; Sorafenib; Sulfasalazine | 2021 |
Rational drug design of indazole-based diarylurea derivatives as anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer-Aided Design; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Indazoles; Molecular Docking Simulation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib; Structure-Activity Relationship; Urea | 2017 |
A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Cluster Analysis; Data Mining; Databases, Factual; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Linear Models; Microarray Analysis; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2017 |
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Multiple; Female; Galectin 1; Gene Expression Regulation; Humans; Mice, Inbred BALB C; Molecular Imaging; Neoplasms; Optical Imaging; Positron-Emission Tomography; Sorafenib | 2018 |
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bufanolides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2018 |
Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Female; Hepacivirus; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; RNA, Viral; Sorafenib; Viral Load; Virus Replication | 2018 |
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib | 2018 |
Improvement of physicochemical properties of nanocolloidal carrier loaded with low water solubility drug for parenteral cancer treatment by Response Surface Methodology.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Cell Survival; Chemical Phenomena; Chemistry, Pharmaceutical; Colloids; Drug Carriers; Drug Stability; Hep G2 Cells; HT29 Cells; Humans; Infusions, Parenteral; Mice; Nanoparticles; Neoplasms; NIH 3T3 Cells; Oils; Solubility; Sorafenib; Viscosity; Water | 2019 |
The release and activity of HMGB1 in ferroptosis.
Topics: Animals; Autophagy; Carbolines; Cell Death; Cell Line, Tumor; Chloroquine; Ferritins; Fibroblasts; HMGB1 Protein; Humans; Immunity, Innate; Inflammation; Iron Overload; Lipid Peroxidation; Macrolides; Mice; Neoplasms; Oximes; Piperazines; Sorafenib; Sulfonamides; Toll-Like Receptor 4 | 2019 |
CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Topics: Animals; Antibodies, Bispecific; Antibody Affinity; Antibody Specificity; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; CD24 Antigen; Cell Degranulation; Cell Line, Tumor; Cytokines; Disease Models, Animal; Drug Synergism; Genetic Vectors; Histocompatibility Antigens Class I; Humans; Immunoglobulin Fc Fragments; Immunotherapy; Killer Cells, Natural; Leukocytes, Mononuclear; Mice; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Fc; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent?
Topics: Antineoplastic Agents; Drug Approval; Equivalence Trials as Topic; Humans; Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib; United States; United States Food and Drug Administration | 2019 |
Psammaplysin F increases the efficacy of bortezomib and sorafenib through regulation of stress granule formation.
Topics: Animals; Bortezomib; Chlorocebus aethiops; Cytoplasmic Granules; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; Sorafenib; Spiro Compounds; Tyrosine; Vero Cells | 2019 |
Quantitative and high drug loading of self-assembled prodrug with defined molecular structures for effective cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Female; Glutathione; Humans; Mice; Nanoparticles; Neoplasms; Polyethylene Glycols; Prodrugs; Sorafenib | 2019 |
[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Cell Transformation, Neoplastic; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Radioactive Tracers; Radiochemistry; Rats; Sorafenib | 2013 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Doxorubicin; Drug Delivery Systems; Female; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Optical Imaging; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sorafenib | 2013 |
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Janus Kinase 2; Neoplasms; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.
Topics: Alkynes; Antineoplastic Agents; Azides; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Cycloaddition Reaction; Drug Carriers; Humans; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Porosity; Silicon; Sorafenib | 2014 |
Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
Topics: Antineoplastic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Lapatinib; Metabolic Clearance Rate; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Reproducibility of Results; Sorafenib; Spectrophotometry, Ultraviolet | 2014 |
ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells.
Topics: Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; Herpesvirus 4, Human; Humans; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Reactive Oxygen Species; Sorafenib | 2014 |
Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Contrast Media; Drug Carriers; Hep G2 Cells; Histidine; Humans; Hydrogen-Ion Concentration; Lactic Acid; Magnetic Resonance Imaging; Mice; Nanoparticles; Neoplasms; Niacinamide; Particle Size; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Polymers; Radiography; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Transplantation, Heterologous | 2014 |
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Decision Making; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Netherlands; Niacinamide; Phenylurea Compounds; Pyrroles; Quality of Life; Self Report; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous | 2014 |
Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Decision Support Techniques; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Registries; Regression Analysis; Sorafenib | 2014 |
Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Humans; L-Lactate Dehydrogenase; Necrosis; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured | 2014 |
Multifunctional porous silicon nanoparticles for cancer theranostics.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Humans; Male; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Silicon; Sorafenib; Theranostic Nanomedicine | 2015 |
Nexavar/Stivarga and viagra interact to kill tumor cells.
Topics: Apoptosis; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Signal Transduction; Sildenafil Citrate; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2015 |
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Topics: Animals; Bacterial Infections; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Escherichia coli; Heat-Shock Proteins; Humans; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Polynucleotide 5'-Hydroxyl-Kinase; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Virus Diseases | 2015 |
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Models, Statistical; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Survival Analysis | 2015 |
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Female; Gene Expression Profiling; Humans; Infant; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sorafenib; Transcriptome; Treatment Outcome; Young Adult | 2016 |
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome | 2015 |
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Topics: Animals; Antineoplastic Agents; CD40 Ligand; Cell Proliferation; CTLA-4 Antigen; Female; Forkhead Transcription Factors; Humans; Immunotherapy; Interferon-gamma; Interleukin-17; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Interleukin-6; Jurkat Cells; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; NFATC Transcription Factors; Niacinamide; Ovalbumin; Peptide Fragments; Phenylurea Compounds; Promoter Regions, Genetic; Receptors, Antigen, T-Cell; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2015 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Sulfonamides; Vemurafenib | 2016 |
In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Liberation; Embolization, Therapeutic; Female; Fibroblasts; Human Umbilical Vein Endothelial Cells; Mice, Inbred BALB C; Microspheres; Neoplasms; Niacinamide; Phenylurea Compounds; Polyesters; Sorafenib; Tumor Burden | 2016 |
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Asian People; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Everolimus; Feasibility Studies; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Sorafenib; Young Adult | 2016 |
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.
Topics: Antineoplastic Agents; Capecitabine; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pharmacovigilance; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taxoids; Treatment Outcome | 2016 |
Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Blood Pressure; Carotid Arteries; Cohort Studies; Cross-Sectional Studies; Female; Humans; Indoles; Male; Manometry; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pulse Wave Analysis; Pyrroles; Sorafenib; Sunitinib; Vascular Stiffness | 2017 |
Challenges and pitfalls of combining targeted agents in phase I studies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Death; Cell Line, Tumor; Drug Synergism; fas Receptor; Humans; Hydroxamic Acids; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat | 2008 |
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
Cutaneous drug eruptions induced by sorafenib: a case series.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Female; Humans; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality Control; Reference Standards; Reproducibility of Results; Sorafenib; Specimen Handling; Spectrophotometry, Ultraviolet | 2009 |
Selecting promising treatments in randomized Phase II cancer trials with an active control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials, Phase II as Topic; Control Groups; Endpoint Determination; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2009 |
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Cytokines; Disease-Free Survival; Endothelial Cells; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
Multiple Histology Phase II Trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Computer Simulation; Humans; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sarcoma; Sorafenib; Treatment Outcome | 2009 |
Array of cutaneous adverse effects associated with sorafenib.
Topics: Benzenesulfonates; Biopsy, Needle; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunohistochemistry; Incidence; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Risk Assessment; Skin Diseases; Sorafenib | 2009 |
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib | 2010 |
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Computational Biology; Humans; Image Interpretation, Computer-Assisted; Mice; Mice, SCID; Microvessels; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2009 |
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cohort Studies; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Rapid development of hypertension by sorafenib: toxicity or target?
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Pressure; Drug Delivery Systems; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Mice; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Risk of bleeding not increased by sorafenib or sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2010 |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Proliferation; Cell Survival; Down-Regulation; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Humans; Hydrogen Peroxide; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sorafenib; Tumor Cells, Cultured | 2010 |
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; DNA, Neoplasm; Female; Foot Dermatoses; Genotype; Hand Dermatoses; Humans; Hypertension; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
Topics: Animals; Benzenesulfonates; Cell Line, Tumor; Child; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Drug Eruptions; Female; Folliculitis; Humans; Keratosis; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Skin; Sorafenib | 2010 |
Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Hydrogen Bonding; Molecular Conformation; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tosyl Compounds | 2011 |
An approach to meta-analysis of dose-finding studies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Humans; Maximum Tolerated Dose; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Tegafur | 2011 |
Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; HT29 Cells; Humans; Inhibitory Concentration 50; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Rhodanine; Sorafenib; Structure-Activity Relationship | 2011 |
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Endonucleases; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Burden; X-ray Repair Cross Complementing Protein 1; Xenograft Model Antitumor Assays | 2011 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Female; Glutamates; Guanine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution | 2011 |
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Female; Humans; Male; Neoplasms; Niacinamide; Orosomucoid; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Serum Albumin; Sorafenib; Young Adult | 2011 |
Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cattle; Cell Line, Tumor; Drug Carriers; Female; Hemolysis; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Sorafenib | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cells, Cultured; Female; Humans; Keratinocytes; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyridines; raf Kinases; ras Proteins; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Skin; Skin Neoplasms; Sorafenib; Tumor Suppressor Protein p53; Ultraviolet Rays | 2012 |
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Pilot Projects; Polymorphism, Genetic; Prostatic Neoplasms; Pyridines; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |
RAIN-Droplet: a novel 3D in vitro angiogenesis model.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Imaging, Three-Dimensional; Microscopy, Confocal; Microscopy, Electron, Transmission; Microvessels; Models, Biological; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spheroids, Cellular | 2012 |
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Toxicity Tests; Treatment Outcome; Young Adult | 2012 |
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Risk Factors; Skin; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Real-Time Polymerase Chain Reaction; RNA Interference; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.
Topics: Animals; Antineoplastic Agents; Glucuronic Acid; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Solute Carrier Organic Anion Transporter Family Member 1B3; Sorafenib | 2013 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2013 |
Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2005 |
Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Clinical Trials as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Clinical trials referral resource.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Referral and Consultation; Sorafenib; United States | 2005 |
Drug approval triggers debate on future direction for cancer treatments.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Approval; Drug Design; Enzyme Inhibitors; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Sorafenib; United States; United States Food and Drug Administration | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Multiple Myeloma; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2006 |
A tale of two drugs.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzenesulfonates; Clofarabine; Drug Approval; Drug Design; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome | 2007 |
ASCO 2007: plenary top 5.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Medical Oncology; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Societies, Medical; Sorafenib; United States | 2007 |
Examining heterogeneity in phase II trial designs may improve success in phase III.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Confounding Factors, Epidemiologic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Treatment Outcome | 2008 |
Quantifying hypertension in patients with cancer treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2008 |